IP Library Granted Patent US 10,238,606
Granted Patent B2
US 10,238,606 · App. 15/466,305 · Granted Mar 26, 2019

Pharmaceutical compositions for the treatment of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,606
App. No.
15/466,305
Granted
Mar 26, 2019
Kind
B2
Abstract

Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

Claims (8)

1. A kit comprising:

a 14 day supply of capsules for eradicating H. pylori infection with an effectiveness greater than 80%, the 14 day supply including 168 all-in-one capsules filled with minitablets, wherein each capsule comprises 12.5 mg rifabutin/250 mg amoxicillin mixed minitablets and 10 mg omeprazole minitablets; and

instructions to administer orally 4 capsules from the 14 day supply three times daily for a total daily oral dose of 150 mg rifabutin, 3000 mg amoxicillin, and 120 mg omeprazole for 14 days.

2. The kit of claim 1 , wherein the 14 day supply of capsules is sufficiently designed to result in an eradication rate greater than 85%.

3. The kit of claim 1 , wherein the 14 day supply of capsules is sufficiently designed to result in an eradication rate greater than 90%.

4. The kit of claim 1 , wherein the 14 day supply of capsules is sufficiently designed to result in an eradication rate greater than 95%.

5. The kit of claim 1 wherein the amoxicillin is amoxicillin trihydrate.

6. The kit of claim 1 wherein the omeprazole is magnesium omeprazole.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 19, 2024
From: HCR REDHILL SPV, LLC
To: REDHILL BIOPHARMA INC.; REDHILL BIOPHARMA LTD.
Reel/Frame 068034/0458 →
SECURITY INTEREST Recorded Feb 24, 2020
From: REDHILL BIOPHARMA LTD.
To: HCR COLLATERAL MANAGEMENT, LLC, AS ADMINSTRATIVE AGENT
Reel/Frame 051909/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2018
From: FATHI, REZA; RADAY, GILEAD; GOLDBERG, GUY; GOSSELIN, PATRICK
To: REDHILL BIOPHARMA LTD.
Reel/Frame 047359/0273 →